Does Weight Loss Intervention Improve Persistent AF? - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Does Weight Loss Intervention Improve Persistent AF?

Randomized trial found significant weight loss did not improve atrial fibrillation severity or burden in older patients with persistent disease.

  • By

  • Andrea Surnit

  • June 15, 2026

  • 4 min

Share

Clinical Scorecard: Does Weight Loss Intervention Improve Persistent AF?

At a Glance

CategoryDetail
Condition
Key MechanismsWeight loss through a low-calorie diet and behavioral support, as reported in the study.
Target Population
Care Setting

Key Highlights

  • 118 patients enrolled in the LOSE-AF trial.
  • Intervention group lost 10% of body weight at 8 months.
  • No significant differences in AF severity or burden between groups.
  • 42% of intervention group free of AF vs 49% in control group at follow-up.
  • No severe adverse events reported.

Guideline-Based Recommendations

Diagnosis

  • Persistent AF diagnosed in patients aged 60 to 85 with BMI ≥ 27, as per study criteria.

Management

  • Low-calorie diet and behavioral support program for weight loss, as utilized in the trial.

Monitoring & Follow-up

  • 14-day electrocardiographic monitoring for AF burden assessment, as conducted in the study.

Risks

  • No significant safety concerns reported during the intervention, as stated in the findings.

Patient & Prescribing Data

Moderate dietary weight loss observed, but no impact on AF symptoms or burden, as reported.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Does Weight Loss Intervention Improve Persistent AF?

    • by Andrea Surnit

    • June 15, 2026

    Related Content

    Comment on “Life’s essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants” and the inclusion of sleep in cancer focused guidelines

    Menopause may be underdocumented in EHRs

    Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.

    Tirzepatide’s cardiovascular effects in clinical practice

    Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.